Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB -3.04%10 Pretax Margin % is -3,925.63% as of Mar. 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Upstream Bio ranks worse than 89.05% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Upstream Bio's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-40.59 Mil. Upstream Bio's Revenue for the
three
months ended in Mar. 2026 was $1.03 Mil. Therefore, Upstream Bio's pretax margin for the quarter that ended in Mar. 2026 was -3,925.63%.
The historical rank and industry rank for Upstream Bio's Pretax Margin % or its related term are showing as below:
UPB'
s Pretax Margin % Range Over the Past 10 Years
Min: -5026.03 Med: -2309.68 Max: -862.9
Current: -4718.96
UPB's Pretax Margin % is ranked worse than 89.05% of 941
companies
in the Biotechnology industry
Industry Median: -89.42
vs UPB: -4718.96
Upstream Bio (NAS:UPB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Upstream Bio Pretax Margin % Related Terms
Upstream Bio Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Upstream Bio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPB vs OABI, VNDA, LXEO: Pretax Margin % Comparison
For the Biotechnology subindustry, Upstream Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Upstream Bio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Upstream Bio (UPB) has a Pretax Margin % of -3,925.63% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Upstream Bio and its competitors. According to the industry distribution chart, Upstream Bio ranks #838 out of 941 companies in the Biotechnology industry, placing it in the top 89.1%.
Is Upstream Bio's Pretax Margin % too high?
Upstream Bio's current Pretax Margin % is -3,925.63%. Based on the distribution chart, Upstream Bio ranks #838 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's Pretax Margin % compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #838 out of 941 companies for Pretax Margin %. This places Upstream Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Upstream Bio and its competitors. Upstream Bio's current Pretax Margin % is -3,925.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current Pretax Margin % of -3,925.63%. The current Pretax Margin % is -3,925.63%. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Upstream Bio (UPB), the current Pretax Margin % is -3,925.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
